Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with nab-paclitaxel, gemcitabine, and cisplatin for advanced biliary tract cancer
ChiCTR2100049404Phase 2Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Aug 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel, gemcitabine and cisplatin in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more, sponsored by Xinhua Hospital. Primary endpoint: Objective response rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxelgemcitabinecisplatin
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2100049404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049404.